Leukemia panel date and time:
- Foghorn Presenter:
Alfonso Quintas-Cardama , Chief Medical Officer - Please find a link to the panel here.
Management will also participate in one-on-one meetings during the conference.
A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contacts:
gdearborn@foghorntx.com
khellsvik@foghorntx.com
adam@scientpr.com
pkelleher@lifesciadvisors.com
Source:
2024 GlobeNewswire, Inc., source